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Abstract
Background: Despite a substantial progress in diagnosis and therapy, acute myocardial infarction (MI) is a major cause of
mortality in the general population. A novel insight into the pathophysiology of myocardial infarction obtained by studying
gene expression should help to discover novel biomarkers of MI and to suggest novel strategies of therapy. The aim of our
study was to establish gene expression patterns in leukocytes from acute myocardial infarction patients.
Methods and Results: Twenty-eight patients with ST-segment elevation myocardial infarction (STEMI) were included. The
blood was collected on the 1st day of myocardial infarction, after 4–6 days, and after 6 months. Control group comprised 14
patients with stable coronary artery disease, without history of myocardial infarction. Gene expression analysis was
performed with Affymetrix Human Gene 1.0 ST microarrays and GCS3000 TG system. Lists of genes showing altered
expression levels (fold change .1.5, p,0.05) were submitted to Ingenuity Pathway Analysis. Gene lists from each group
were examined for canonical pathways and molecular and cellular functions. Comparing acute phase of MI with the same
patients after 6 months (stable phase) and with control group we found 24 genes with changed expression. In canonical
analysis three pathways were highlighted: signaling of PPAR (peroxisome proliferator-activated receptor), IL-10 and IL-6
(interleukin 10 and 6).
Conclusions: In the acute phase of STEMI, dozens of genes from several pathways linked with lipid/glucose metabolism,
platelet function and atherosclerotic plaque stability show altered expression. Up-regulation of SOCS3 and FAM20 genes in
the first days of myocardial infarction is observed in the vast majority of patients.
Citation: Kiliszek M, Burzynska B, Michalak M, Gora M, Winkler A, et al. (2012) Altered Gene Expression Pattern in Peripheral Blood Mononuclear Cells in Patients
with Acute Myocardial Infarction. PLoS ONE 7(11): e50054. doi:10.1371/journal.pone.0050054
Editor: Rakesh Kukreja, Virginia Commonwealth University Medical Center, United States of America
Received March 27, 2012; Accepted October 15, 2012; Published November 21, 2012
Copyright:  2012 Kiliszek et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grant R13 0001 06 from The National Centre for Research and Development (NCBiR). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kiliszek@mp.pl (MK); atka@ibb.waw.pl (BB)
Introduction
Acute myocardial infarction (MI) remains the leading cause of
death despite the substantial progress in diagnosis and therapy in
recent decades. In the acute phase of MI increased leukocyte
count, a non-specific marker of inflammation, is the risk factor for
future cardiovascular events and predicts mortality in those with
STEMI [ST-segment elevation MI], NSTEMI (non-STEMI) or
unstable angina [1,2]. It has also been shown that an elevated
leukocyte count predicts 1-year mortality independently of the risk
factors for coronary artery disease across the entire spectrum of
acute coronary syndromes (ACS) [3]. The mechanisms linking
activation of inflammation and ACS are complex – inflammation
seems to be linked to the initiation and progression of atheroscle-
rosis [4]. Obtaining novel insights into the pathophysiology of
myocardial infarction by analyzing gene expression patterns in
leucocytes should aid the discovery of novel biomarkers of MI and
elaboration of novel therapeutic strategies. The aim of our pilot
study was the first attempt at establishing leukocyte gene
expression signatures of the acute phase of MI.
Materials and Methods
Patients
Patients presenting with STEMI were included in the Ist Chair
and Departament of Cardiology of Medical University of Warsaw
in 2010. We sought to include consecutive patients that agreed to
participate in the study (due to technical aspects of blood
collection, only patients admitted between Sunday and Thursday
were taken into consideration). All the patients underwent
coronary angiography and angioplasty of infarct related artery.
Pharmacological treatment was according to current guidelines
[5]. Blood was collected on the 1st day of myocardial infarction
(admission), after 4–6 days (discharge), and after 6 months.
Participation in the study had no influence on the pharmacological
treatment and procedures underwent by the patients. Control
PLOS ONE | www.plosone.org 1 November 2012 | Volume 7 | Issue 11 | e50054
group comprised patients with proven coronary artery disease:
with coronary angiography (at least one stenosis exceeding 50% or
previous coronary angioplasty of previous coronary artery bypass
graft), or with non-invasive tests (positive exercise test) and no
history of myocardial infarction. The study was approved by the
Bioethics Committee of the Medical University of Warsaw and all
patients gave written informed consent.
RNA Isolation
Sodium-heparinized blood was collected from 28 patients at the
three time points. Peripheral blood mononuclear cells (PBMC)
were purified using BD VacutainerH CPTTM Cell Preparation
Tube according to the manufacturer’s instructions (Becton,
Dickinson and Co. Franklin Lakes, NJ,USA).
Total RNA was isolated from PBMC with the MagNA Pure
Compact System (Roche Diagnostics GmbH, Germany) according
to the manufacturer’s recommendations. RNA samples were
quantified by UV absorption (Nanodrop, LabTech International,
UK) and their quality was checked with the RNA 600 Nano Assay
Kit using Bioanalyzer in accordance with the manufacturer’s
procedures (Agilent, Santa Clara, CA, USA). Samples with an
RNA integrity number of eight or above were considered suitable
for use in microarrays. RNA samples were stored at 280uC until
further analysis.
cDNA Microarrays
RNA (100 ng) was reverse transcribed, amplified, and labeled
with biotin using the whole transcript sense target labeling kit and
hybridized for 16 h at 45uC to Human Gene 1.0 ST arrays
(Affymetrix, Santa Clara,CA, USA), according to the manufac-
turer’s instructions. Following hybridization, the probe arrays were
washed and stained on a fluidics station and immediately scanned
on an Affymetrix GCS 3000 GeneArray Scanner.
Data Analysis of Microarrays
Quality controls were performed using Microarray Suite 5.0
software provided by Affymetrix (www.affymetrix.com) according
to the manufacturer’s recommendations. Affymetrix raw gene
array data were processed using the Partek Genomics Suite
software (Partek Inc., St. Louis, MO, USA).
Comparisons were performed between MI group at day one of
day 4–6 on the one hand and MI group at 6 months or control on
the other. Lists of genes showing significant differences in
expression levels between groups were submitted to Ingenuity
Pathway Analysis (IngenuityH Systems, www.ingenuity.com) for
canonical pathways and subjected to network analyses.
Determination of mRNA Levels by qRTPCR
Total RNA was converted into cDNA using the QuantiTect
Reverse Transcription Kit (QIAGEN, Germany) according to the
manufacturer’s recommendations.
qPCR amplification was performed using a using LightCycler
1.5 and LightCycler 480 Instruments, and LightCycler FastStart
DNA Master SYBR Green I and LightCycler 480 SYBR Green I
Master (Roche Diagnostics GmbH, Germany) according to the
manufacturer’s instructions. The Pfaffl model [6] and the relative
expression software tool (REST-MCS-version 2) [7] were used
to estimate changes in the relative mRNA levels of a 24 genes in
order to validate the results obtained in the microarray study. We
determined the relative expression levels of the selected genes at
the 1st day of myocardial infarction (on admission), 6 months after
MI and in the control group, using samples from six randomly
chosen patients from both groups. Data normalization was carried
out against transcripts of the HPRT and TUBB genes. The
sequences of all primers and qPCR amplification parameters are
available in supplementary data (Table S1).
Statistical analysis. Continuous variables are presented as
mean 6SD (standard deviation). Categorical variables are
presented as frequencies. Statistical significance of the results was
estimated by variance analysis (ANOVA). Differences were
considered statistically significant at a nominal significance of
p,0.05 and a fold change .1.5 in expression between the
admission, discharge and control groups.
Results
Twenty-eight patients with ST-segment elevation myocardial
infarction (STEMI) were included. All the patients completed the
follow-up visit 6 months after admission. The control group
comprised 14 patients. Basic characteristics of the groups are
shown in table 1.
Admission
On the first day of MI 91 genes showed a significantly different
level of expression compared with 6 months after MI. Of those, 57
were annotated, including three pairs of duplicate genes. Of the 54
unique annotated genes with altered expression 51 were up- and
three down-regulated at day 1 versus 6 months (Table S2). In turn,
a comparison of gene expression on the first day of MI with the
control group identified 491 genes a significantly differentially
expressed (212 annotated, including 14 pairs of duplicate genes, 85
were up- and 127 down-regulated, Table S3). Twenty-four genes
were shared between the two comparisons (MI vs. after 6 months
and MI vs. control, Table 2).
Table 1. Major characteristics of the study and control
groups.
Study group Control group p-value
Men/Women 21/7 11/3 0.89
Age* 55.4610.2 67.867.4 0.0003
Anterior myocardial
infarction**
14 (50%) NA NA
Hypertension** 13 (46.4%) 10 (71.4%) 0.23
Diabetes** 5 (17.9%) 3 (21.4%) 0.89
Current smoker** 15 (53.6%) 4 (28.6%) 0.23
Previous myocardial
infarction**
1 (3.6%) NA NA
Body Mass Index (BMI)* 29.464.4 29.564.8 0.58
Left ventricular EF (%)* 46.768.7 59.066.0 0.011
Treatment
Aspirin** 28 (100%) 12 (85.7%) 0.20
Clopidogrel** 28 (100%) 3 (21.4%) ,0.0001
Statin** 28 (100%) 13 (92.8) 0.72
Beta blocker** 28 (100%) 13 (92.8) 0.72
ACE inhibitor** 20 (71.4%) 12 (85.7%) 0.52
Heparin (UFH or
LMWH)**
28 (100%) 0 (0%) ,0.0001
*Mean 6 Standard Deviation.
**number (%);
NA – not applicable.
doi:10.1371/journal.pone.0050054.t001
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In a canonical analysis of the genes with altered expression
several pathways were found, the most significant being: signaling
of PPAR (peroxisomal proliferator-activated receptor), IL-6
(interleukin 6) signaling, and IL-10 (interleukin 10) signaling.
These pathways were common for both comparisons (Figure 1).
Additionally, a comparison between day one and after 6 months
revealed significant changes in glucocorticoid receptor signaling
and activation of LXR/RXR (liver 6 receptor/retinoid 6
receptor). In contrast, analysis of the day one MI group versus
the control highlited genes associated with Complement System,
Coagulation System, Natural Killer Cell Signaling, and Extrinsic
Prothrombin Activation Pathway.
In the molecular and cellular function categories Cellular
Growth and Proliferation, Cell-To-Cell Signaling and Interaction,
and Cell Movement were markedly changed in both analyses.
To validate the microarray results, mRNA levels of twenty-four
genes shared between the two comparisons were quantified by
qRT-PCR (Table 3). Results of validation confirmed the
microarray data and for most of the genes the fold-changes
calculated by qRT-PCR exceeded the microarray ones.
Discharge
On the 4th–6th day after MI expression of 34 genes was changed
relative to 6 months after MI: 18 with annotation including two
pairs and one gene represented by seven probes, which makes 10
unique genes, all upregulated (Table S4). In a canonical analysis
five most significant pathways were: Primary Immunodeficiency
Signaling, B Cell Development; Communication between Innate
and Adaptive Immune Cells; Systemic Lupus Erythematosus
Signaling; Role of Macrophages, Fibroblasts and Endothelial Cells
in Rheumatoid Arthritis.
Analysis of 4th–6th day after MI versus the control group
indicated 302 differentially expressed genes with 98 of them
annotated, including three pairs of duplicates; 26 up- and 72
down-regulated (Table S5). Association with Hematopoiesis from
Pluripotent Stem Cells, Primary Immunodeficiency Signaling,
Natural Killer Cell Signaling, Complement System, and EIF2
Signaling canonical pathways was found.
Genes Shared between Admission and Discharge
Taking into account genes common to the two analyses of gene
expression on admission and on discharge versus after 6 months,
Table 2. Differentially expressed genes common to both analyses: admission versus 6 months after MI and admission versus
control.
Admission vs 6 months Admission vs control
Fold Change p-value Fold Change p-value Symbol Entrez Gene Name
21.505 1.36E209 21.664 7.16E–07 MYBL1 v-myb myeloblastosis viral oncogene homolog
(avian)-like 1
21.563 1.51E207 22.006 2.14E–05 KLRC4 killer cell lectin-like receptor subfamily C, member 4
21.578 2.30E206 22.213 6.33E–05 KLRC2 killer cell lectin-like receptor subfamily C, member 2
1.518 5.04E213 2.236 1.07E–02 TMEM176A transmembrane protein 176A
1.570 1.68E216 1.753 2.51E–08 ST14, MT-SP1/matriptase suppression of tumorigenicity 14 (colon carcinoma)
1.573 5.36E205 1.732 1.74E–04 HBEGF heparin-binding EGF-like growth factor
1.577 5.82E216 1.950 1.62E–09 ASGR2 asialoglycoprotein receptor 2
1.584 5.95E214 1.989 3.39E–10 STAB1 stabilin 1
1.587 3.26E203 1.605 2.50E–02 EGR2 early growth response 2
1.589 1.07E206 1.555 1.48E–03 FMN1 (includes EG:296512) formin 1
1.601 6.36E212 1.533 2.03E–04 CR1 complement component (3b/4b) receptor 1 (Knops
blood group)
1.611 3.11E213 1.674 2.68E–05 RNASE1 ribonuclease, RNase A family, 1 (pancreatic)
1.629 1.88E212 1.837 1.40E–06 TCN2 transcobalamin II
1.638 4.61E211 1.512 1.62E–04 VSIG4 V-set and immunoglobulin domain containing 4
1.669 6.74E212 1.586 3.42E–05 CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide
1
1.693 6.24E213 1.771 3.90E–05 DYSF dysferlin, limb girdle muscular dystrophy 2B
(autosomal recessive)
1.761 1.99E211 1.769 1.33E–04 RNASE2 ribonuclease, RNase A family, 2 (liver, eosinophil-
derived neurotoxin)
1.778 9.45E213 1.711 1.84E–07 PPARG peroxisome proliferator-activated receptor gamma
1.904 9.39E211 1.631 1.25E–03 FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64)
1.945 1.01E210 1.972 2.16E–05 FAM20A family with sequence similarity 20, member A
1.958 1.71E215 1.732 4.98E–05 AQP9 aquaporin 9
2.066 5.51E205 1.955 4.17E–03 EGR1 early growth response 1
2.339 9.00E214 2.008 4.14E–04 HP haptoglobin
2.929 1.60E220 2.443 5.10E–09 SOCS3 suppressor of cytokine signaling 3
doi:10.1371/journal.pone.0050054.t002
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only two transcripts showed significantly altered expression:
FAM20A and SOCS3. In contrast, when the same admission
and discharge groups were compared with the control 75 genes
were shared between the two comparisons, including 39 down-
regulated small non-coding RNA transcripts (Table 4).
Additionally, we undertook a patient-by-patient analysis of the
most differently expressed genes between all groups. The direction
of change was the same in all patients although the relative levels
of expression differed markedly between patients (Figure 2).
Discussion
We have shown here that in leukocytes of STEMI patients tens
of genes show altered expression during or soon after MI relative
to the stable coronary artery disease. Interestingly, at the day of
the infarct they include mainly genes and pathways directly or
indirectly linked with lipid/glucose metabolism, platelet function
and atherosclerotic plaque stability. On discharge, many genes
related to specific immune response (encoding immunoglobulins)
show altered expression. Comparing the admission and the
Figure 1. Top canonical pathways associated with acute phase of STEMI. Ingenuity Pathway Analysis of gene sets differentially expressed on
the first day of myocardial infarction versus 6 months after MI or versus control group was performed. Functional categories are represented on the x-
axis. The significance is expressed as the negative exponent on the p-value calculated for each function on the y-axis of the diagram, increasing with
bar height.
doi:10.1371/journal.pone.0050054.g001
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discharge profiles with the control group, a strikingly high number
of small non-coding RNA transcripts (most frequent small
nucleolar RNA, snoRNA) show altered expression. Those
snoRNAs are known to act as guide molecules for site-specific
methylation and pseudouridylation of other RNAs. snoRNA-
guided modifications of mRNA seem possible and could affect
splicing, translation or mRNA stability. However, the clinical
significance of snoRNA is not known [8].
Gene Expression
Below we discuss selected literature references indicating a
possible relevance of individual genes showing altered expression
in this study (see Table 2) to the functioning of the cardiovascular
system.
We have shown up-regulation of SOCS3 and FAM20 genes in
the first 4–6 days of myocardial infarction. SOCS3 is one of the
eight proteins of the SOCS group that block the JAK (Janus
kinase) tyrosine kinase activity and the activation of STAT factors
[9]. Expression of SOCS3 has been shown to be significantly
reduced in balloon-injured porcine coronary arteries [10].
Recently it was reported that the progression of LV remodeling
after AMI was prevented in SOCS3-deficient mice. SOCS3
deletion enhanced multiple cardioprotective signaling pathways
including STAT3, AKT, and extracellular signal-regulated kinase
(ERK)-1/2, while inhibiting myocardial apoptosis and fibrosis
[11].
The FAM20 family comprises secreted proteins with potential
roles in regulating differentiation and functioning of hematopoietic
and other tissues. The FAM20A mRNA is only expressed during
early stages of hematopoietic development [12]. The role of
FAM198B is unknown.
ST14 (MT-SP1/matriptase) of plays roles in growth factor
activation, receptor activation and inactivation, protease activa-
tion, and ectodomain shedding [13]. In atherosclerotic lesions,
enhanced mRNA and protein expression of ST14 was found
relative to nondiseased vessels [14]. Asialoglycoprotein receptor
(ASGPR) is a hepatic lectin responsible for selective binding and
internalization of galactose/N-acetylgalactosamine-terminating
glycoproteins by hepatic parenchymal cells [15]. ASGR plays a
role in regulating platelet life span and activation [16], which
suggest a potential link of ASGR with coronary disease and acute
coronary syndromes. The aquaporin (AQP) family members are
fundamental in transmembrane water movements [17]. The
specific function of AQP9 is to maximize glycerol influx and urea
efflux during gluconeogenesis, as this channel is more permeable
to glycerol and urea than to water [18]. Using an AQP9-knockout
mice model it has been shown that AQP9 is important for hepatic
glycerol metabolism and may play a role in glycerol and glucose
metabolism in diabetes mellitus [19].
Early growth response-1 (EGR1) plays a role in the pathogenesis
of atherosclerotic lesions, intimal thickening after acute vascular
injury, ischemic pathology, angiogenesis, allograft rejection, and
cardiac hypertrophy. Aditionally, EGR-1 regulates expression of
molecules critically linked with atherogenesis and lesion progres-
sion [20,21,22]. Peroxisome proliferator-activated receptor G
(PPARG), a member of the PPAR subfamily of nuclear hormone
receptors, has a key role in adipogenesis, insulin sensitivity, and
glucose and lipid metabolism, and also plays a major role in
vascular biology, modulating atherosclerosis progression and
vascular endothelial function [23,24]. Killer cell lectin-like
receptor subfamily C, member 2 (KLRC2) and member 4
(KLRC4) are expressed primarily in natural killer (NK) cells and
are a family of transmembrane proteins characterized by a type II
membrane orientation and the presence of a C-type lectin domain.
NK cells are an important component of the innate immune
system through target cell killing and cytokine production. A direct
evidence for NK cell involvement in atherogenesis is scant,
although some researchers have localized NK cells to the human
atherosclerotic plaque [25,26]. RNASE2– RNase A family, 2
(liver, eosinophil-derived neurotoxin) is a distinct cationic protein
of the eosinophil’s large specific granule known primarily for its
ability to induce ataxia, paralysis, and central nervous system
cellular degeneration [27]. FCGR1A – Fc fragment of IgG, high
affinity 1A, receptor (CD64) is unique within the FCGR family
which mediates important immune defense functions by inducing
cell surface changes on human leukocytes [28,29]. Activating
FCGRs can induce phagocytosis, antigen presentation, the
production of reactive oxygen species (ROS) and cytokines [28].
Canonical Analysis
Activation of PPAR changes gene transcription to modulate
several clinically important metabolic functions: it improves the
lipid profile and corrects hyperglycaemia and insulin resistance
[30]. Interestingly, PPAR and retinoid 6 receptor (RXR)
cooperate in metabolic regulation. Numerous PPAR agonists are
used in clinical setting (fibrates) or are currently under investiga-
tion for therapeutic application (thiazolidinediones).
Table 3. Validation of microarray data using qRT-PCR.
Mean expression ratio (S.D.)
Gene Symbol Admission vs 6 months Admission vs control
KLRC2 0.59 (0.43)NS 0.22 (0.13)*
MYBL1 0.55 (0.19)NS 0.56 (0.20)*
KLRC4 0.51 (0.34)NS 0.65 (0.41)NS
SOCS3 12.63 (5.23)*** 5.42 (2.21)**
FAM20A 6.31 (3.09)*** 3.56 (1.62)*
EGR1 5.82 (4.54)* 6.64 (5.85)*
PPARG 4.20 (1.71)*** 4.28 (1.76)**
HP 4.00 (2.75)NS 3.12 (1.88)NS
HBEGF 3.79 (2.05)* 2.77 (1.53)NS
EGR2 3.68 (3.26)NS 6.93 (6.60)NS
VSIG4 3.62 (1.42)** 3.72 (1.53)*
AQP9 3.28 (1.34)** 2.44 (0.87)*
STAB1 2.97 (1.08)* 1.64 (0.45)NS
ST14 2.79 (0.81)*** 1.61 (0.45) NS
RNASE2 2.79 (1.06)** 2.08 (0.76)NS
CR1 2.67 (0.83)** 2.88 (1.01)NS
RNASE1 2.67 (0.91)* 3.07 (1.16)NS
CYP1B1 2.65 (0.77)** 1.78 (0.57)NS
FCGR1A 2.65 (1.07)* 1.92 (0.68)NS
ASGR2 2.49 (0.92)* 2.45 (0.83)*
DYSF 2.48 (1.05)NS 1.60 (0.58)NS
TCN2 2.05 (0.57)* 1.57 (0.42)NS
TMEM176A 2.00 (0.98)NS 8.77 (5.20)**
FMN1 1.72 (0.63)NS 3.64 (1.82)NS
***p,0.001; **p,0.01; *p,0.05; NS – not significant.
All genes abbreviations are explained in Table 2.
doi:10.1371/journal.pone.0050054.t003
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Table 4. Differentially expressed genes common to both analyses: admission versus control and discharge versus control.
Admission vs control Discharge vs control
Fold Change p-value Fold Change p-value Symbol Entrez Gene Name
23.501 4.71E–19 23.030 2.49E–16 SNHG12 small nucleolar RNA host gene 12 (non-protein coding)
23.155 8.66E–23 23.084 2.87E–22 SNORA24 small nucleolar RNA, H/ACA box 24
23.090 3.79E–06 23.118 3.24E–06 GPR128 G protein-coupled receptor 128
22.777 1.40E–15 22.479 2.52E–13 SNORA20 small nucleolar RNA, H/ACA box 20
22.617 3.72E–05 21.739 1.44E–02 CLC Charcot-Leyden crystal protein
22.448 4.05E–23 212.134 5.82E–19 TAF1D TATA box binding protein (TBP)-associated factor, RNA
polymerase I, D, 41kDa
22.308 1.07E–11 22.086 8.97E–10 SNORD105 small nucleolar RNA, C/D box 105
22.301 5.66E–12 22.065 7.27E–10 ANKRD32 ankyrin repeat domain 32
22.293 2.24E–16 22.026 3.11E–13 SCARNA6 small Cajal body-specific RNA 6
22.256 6.24E–15 22.095 3.85E–13 RPL13A ribosomal protein L13a
22.227 1.22E–10 22.062 3.14E–09 RABGGTB Rab geranylgeranyltransferase, beta subunit
22.213 6.33E–05 21.938 7.42E–04 KLRC2 killer cell lectin-like receptor subfamily C, member 2
22.110 4.52E–06 21.615 2.36E–03 MS4A3 membrane-spanning 4-domains, subfamily A, member 3
(hematopoietic cell-specific)
22.108 1.48E–07 22.005 7.56E–07 SNORD82 small nucleolar RNA, C/D box 82
22.102 4.49E–09 21.960 6.93E–08 SNORD60 small nucleolar RNA, C/D box 60
22.081 3.30E–18 21.964 2.12E–16 SNORD50A small nucleolar RNA, C/D box 50A
22.063 6.32E–08 21.904 1.04E–06 SNORD61 small nucleolar RNA, C/D box 61
22.057 5.83E–09 21.966 3.53E–08 SNHG3 small nucleolar RNA host gene 3 (non-protein coding)
22.053 8.31E–20 22.034 1.67E–19 SNORD15B small nucleolar RNA, C/D box 15B
22.047 1.29E–10 21.949 1.30E–09 SNORD41 small nucleolar RNA, C/D box 41
22.044 3.75E–18 21.863 3.49E–15 SCARNA7 small Cajal body-specific RNA 7
22.012 5.22E–06 21.934 1.55E–05 RNU4-2 RNA, U4 small nuclear 2
22.006 2.14E–05 21.708 8.59E–04 KLRC4 killer cell lectin-like receptor subfamily C, member 4
21.994 6.60E–12 21.906 7.73E–11 SCARNA10 small Cajal body-specific RNA 10
21.983 1.77E210 –1.833 8.01E–09 SNORD1C small nucleolar RNA, C/D box 1C
21.982 1.44E–04 21.709 2.52E–03 KLRC3 killer cell lectin-like receptor subfamily C, member 3
21.972 7.41E–15 21.848 5.48E–13 SNORA68 small nucleolar RNA, H/ACA box 68
21.946 2.00E–12 21.833 6.50E–11 SNORD54 small nucleolar RNA, C/D box 54
21.944 4.72E–15 21.915 1.33E–14 LLPH LLP homolog, long-term synaptic facilitation (Aplysia)
21.824 2.81E–12 21.721 1.16E–10 RMRP RNA component of mitochondrial RNA processing
endoribonuclease
21.784 1.75E–10 21.672 7.20E–09 SCARNA5 small Cajal body-specific RNA 5
21.770 2.35E–10 21.705 2.07E–09 SNHG10 small nucleolar RNA host gene 10 (non-protein coding)
21.755 3.86E–10 21.602 6.87E–08 SNORA3 small nucleolar RNA, H/ACA box 3
21.747 6.99E–08 21.613 2.46E–06 SNORA23 small nucleolar RNA, H/ACA box 23
21.744 6.49E–09 21.517 6.28E–06 CEP78 centrosomal protein 78kDa
21.727 3.33E–05 21.505 1.54E–03 KLRC1 killer cell lectin-like receptor subfamily C, member 1
21.726 7.94E–09 21.507 6.80E–06 SNORD28 small nucleolar RNA, C/D box 28
21.725 1.43E–10 21.647 2.52E–09 HIST1H4A (includes
others)
histone cluster 1, H4a
21.725 5.62E–05 21.506 2.07E–03 SNORD104 small nucleolar RNA, C/D box 104
21.718 5.48E–05 21.521 1.47E–03 DTHD1 death domain containing 1
21.717 5.51E–07 21.544 3.82E–05 SNHG1 small nucleolar RNA host gene 1 (non-protein coding)
21.716 1.83E–16 21.674 1.67E–15 SNORA37 small nucleolar RNA, H/ACA box 37
21.694 2.56E–07 21.635 1.27E–06 SNORD58A small nucleolar RNA, C/D box 58A
21.693 6.32E–08 21.677 1.01E–07 RNU5A-1 RNA, U5A small nuclear 1
21.689 1.23E–10 21.585 7.26E–09 SNORD46 small nucleolar RNA, C/D box 46
Gene Expression in STEMI
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IL-6 seems to have proatherogenic effects. Its serum concen-
tration is elevated in acute myocardial infarction [31] and predicts
events in the follow-up [32]. IL-6 has been shown to enhance fatty
lesion development in mice [33]. IL-6 signaling is regulated by a
family of endogenous JAK kinase inhibitor proteins, suppressors of
cytokine signaling (SOCS) [34]. SOCS3 has a differential effect on
IL-6 and IL-10 receptor signaling: the IL-6 receptor signaling is
down-regulated by SOCS3, whereas that by IL-10 receptor is not
[35]. In mice, leukocyte-derived IL-10 prevents the development
of advanced atherosclerosis and plays a critical role in the
modulation of the cellular and collagen plaque composition [36].
On the other hand, an elevated baseline plasma level of IL-10 has
been reported as a strong and independent predictor of long-term
adverse cardiovascular outcome in patients with acute coronary
syndrome [37].
LXR/RXR plays important roles in cholesterol metabolism and
regulates a number of immune and inflammatory pathways that
have the potential to modulate development of atherosclerotic
lesion [38].
Study Limitations
Since no data on gene expression in STEMI has been published
so far (means, standard deviations, etc.), we conducted a pilot
study with a rather small number of patients. The results should be
confirmed on a larger and independent cohort. Our group was
homogenous (STEMI patients only, with angioplasty of infarct-
related artery) and well-characterized clinically. We compared
expression with two controls: the same group after six months (this
approach has several strengths: age, sex and risk factors are the
same, and the STEMI phase can be compared with the
subsequent stable phase of the coronary artery disease) and an
independent control group with coronary artery disease, but
without myocardial infarction. Our aim was to find genes showing
changed expression specifically during MI, but not those
associated with stable coronary artery disease (that is why we did
not take healthy controls). Thanks to such choice also the
treatment of both groups was comparable, with the exception of
a clopidogrel and – obviously – heparin. Our control group was
older than the experimental group, but when we compared age 1st
Table 4. Cont.
Admission vs control Discharge vs control
Fold Change p-value Fold Change p-value Symbol Entrez Gene Name
21.670 5.57E–07 21.713 1.80E–07 COX7B cytochrome c oxidase subunit VIIb
21.649 3.92E–07 21.514 1.74E–05 PRSS23 protease, serine, 23
21.643 8.00E–09 21.656 4.98E–09 WDR74 WD repeat domain 74
21.619 5.23E–11 21.633 2.76E–11 SNORD59B small nucleolar RNA, C/D box 59B
21.616 6.35E–11 21.546 1.55E–09 RPL7A ribosomal protein L7a
21.600 1.28E–06 21.505 1.91E–05 SNORD14E small nucleolar RNA, C/D box 14E
21.599 3.43E–08 21.525 4.88E–07 SNORD50B small nucleolar RNA, C/D box 50B
21.592 2.70E–06 21.556 7.26E–06 SNORD30 small nucleolar RNA, C/D box 30
21.590 3.50E–09 21.526 4.58E–08 SNORD6 small nucleolar RNA, C/D box 6
21.589 2.19E–11 21.629 3.11E–12 SNORD63 small nucleolar RNA, C/D box 63
21.585 6.35E–08 21.584 6.67E–08 SCARNA1 small Cajal body-specific RNA 1
21.575 3.97E–07 21.520 2.37E–06 SNORA22 small nucleolar RNA, H/ACA box 22
21.550 1.03E–10 21.593 1.19E–11 SNORA19 small nucleolar RNA, H/ACA box 19
21.532 8.76E–12 21.681 2.33E–15 BRK1 BRICK1, SCAR/WAVE actin-nucleating complex subunit
21.531 2.32E–08 21.624 4.74E–10 RNU4ATAC RNA, U4atac small nuclear (U12-dependent splicing)
1.528 7.46E–05 1.554 4.03E–05 C1QB complement component 1, q subcomponent, B chain
1.546 1.92E–06 1.567 9.90E–07 C1QC complement component 1, q subcomponent, C chain
1.568 2.10E–14 1.552 5.55E–14 GPSM3 G-protein signaling modulator 3
1.586 3.42E–05 1.568 3.32E–05 CYP27A1 cytochrome P450, family 27, subfamily A, polypeptide 1
1.597 4.30E–07 1.572 9.32E–07 LGALS9B lectin, galactoside-binding, soluble, 9B
1.620 7.19E–06 1.567 2.59E–05 CD151 CD151 molecule (Raph blood group)
1.629 5.86E–11 1.586 4.11E–10 RAB1B RAB1B, member RAS oncogene family
1.678 1.30E–26 1.545 6.59E–22 MLF2 myeloid leukemia factor 2
1.708 1.09E–14 1.517 2.01E–10 TTYH3 tweety homolog 3 (Drosophila)
1.740 2.15E–13 1.584 2.24E–10 WAS Wiskott-Aldrich syndrome (eczema-thrombocytopenia)
1.747 8.66E–11 1.517 3.89E–07 CA5BP1 carbonic anhydrase VB pseudogene 1
1.765 9.63E–08 1.634 2.64E–06 LGALS9 lectin, galactoside-binding, soluble, 9
1.915 9.75E–03 1.875 1.23E–02 GSTM1 glutathione S-transferase mu 1
1.950 1.62E–09 1.542 3.58E–05 ASGR2 asialoglycoprotein receptor 2
1.972 2.16E–05 1.588 3.00E–03 FAM20A family with sequence similarity 20, member A
doi:10.1371/journal.pone.0050054.t004
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Figure 2. Expression data from microarray experiments for chosen genes. The y-axis represents the log2 normalized intensity of the gene
and the x-axis represents analyzed groups. The line inside the box and whiskers represents the median of the samples in a group. Points present
relative expression levels in individual patients at admission (blue), at discharge (green), 6 month after MI (violet) and from control group (red).
Numbers indicate the coded identity of a particular patient. SOCS3– suppressor of cytokine signaling 3; ST14– MT-SP1/matriptase; AQP 9– aquaporin
9; MYBL1– v-myb myeloblastosis viral oncogene homolog (avian)-like 1; STAB1– stabilin 1; ASGR2– asialoglycoprotein receptor 2.
doi:10.1371/journal.pone.0050054.g002
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or 4th quartile of the study group with the controls, the major
results were the same (data not shown). Obviously the left ventricle
ejection fraction was different – but this cannot be avoided. Other
clinical factors were not significantly different.
Conclusions
ST-segment elevation myocardial infarction alters expression of
several groups of genes. On admission, several genes and pathways
that could be directly or indirectly linked with lipid/glucose
metabolism, platelet function and atherosclerotic plaque stability
were affected (signaling of PPAR, IL-10, IL-6). Analysis at
discharge highlighted specific immune response (upregulation of
immunoglobulins). Highly significant and substantial upregulation
of SOCS3 and FAM20 genes expression in the first 4–6 days of
myocardial infarction in all patients is the most robust observation
of our work.
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